隆基股份(601012.SH):與德力光能簽訂約55.31億元光伏玻璃採購協議
格隆匯 4 月 20日丨隆基股份(601012.SH)公佈,為保證光伏玻璃的長期穩定供應,公司10家全資子公司作為甲方,與蚌埠德力光能材料有限公司(“德力光能”或“乙方”)於2021年4月20日簽訂了五年期光伏玻璃採購協議,根據協議,甲方2022年-2026年向乙方採購光伏玻璃不少於2.5億平方米。
根據卓創周評2021年4月15日公佈的3.2mm光伏玻璃均價28元/平方米(含税)、2.0mm光伏玻璃均價22元/平方米(含税)測算,預估該合同總金額約55.31億元人民幣(不含税),合同總金額佔公司2019年度經審計營業成本的約23.65%(本測算不構成價格承諾)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.